VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Vanrafia (Atrasentan) Demonstrates Significant Kidney Protection in Phase III ALIGN Trial for IgA Nephropathy
Vanrafia (Atrasentan) Demonstrates Significant Kidney Protection in Phase III ALIGN Trial for IgA Nephropathy
Jun 05, 2026 20:38 CST Updated 21:02
Share:
